Australia's most trusted
source of pharma news
Tuesday, 17 September 2024
Posted 4 September 2024 AM
Alongside undergoing rapid growth, BeiGene has been diligently working on building a culture that aligns with flexibility, rolling out augmented programs and initiatives to ensure its employees can balance their work with personal life.
Across the Asia Pacific region, the oncology-focused company well-known for BTK inhibitor Brukinsa and PD-1 inhibitor Tevimbra, currently has more than 450 employees, around 250 of which are located in Australia.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.